Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressBusiness Wire • 11/06/23
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)Business Wire • 10/19/23
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)Business Wire • 10/02/23
Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines ConferenceBusiness Wire • 09/26/23
Better Gene Editing Stock: Intellia Therapeutics vs. Rocket PharmaceuticalsThe Motley Fool • 09/23/23
Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread CarefullyThe Motley Fool • 09/18/23
Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?Seeking Alpha • 09/14/23
Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential 'Value Driver.Barrons • 09/13/23
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon DiseaseBusiness Wire • 09/12/23
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent ProgressBusiness Wire • 08/10/23
Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug TagZacks Investment Research • 06/09/23
Rocket Pharmaceuticals shares rise on FDA fast-track designation for heart disease treatmentMarket Watch • 06/08/23
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)Business Wire • 06/08/23
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon DiseaseBusiness Wire • 05/31/23